Molecular Imaging

分子成像

• 批准号: 8896525
• 负责人: MAX S. WICHA
• 金额: $ 16.98万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8896525
• 关键词: Algorithms; Animal Model; Animals; Antineoplastic Protocols; Area; Autoradiography; Award; Binding; Biological; Biological Markers; Biology; Bone Lymphoma; Brain; Breast; Breast Cancer therapy; CXCR; Caliber; Cancer Center Support Grant; Cancer Diagnostics; Cancer Etiology; Cancer Patient; Cell Surface Receptors; Cells; Clinic; Clinical; Clinical Drug Development; Clinical Research; Clinical Trials; Collaborations; Combined Modality Therapy; Contracts; Contrast Media; Cytotoxic Chemotherapy; Data; Data Set; Detection; Development; Diagnosis; Diffusion; Diffusion Magnetic Resonance Imaging; Disease; Doctor of Philosophy; Dose; Drug Targeting; Early Diagnosis; Early treatment; Enhancing Lesion; Epidermal Growth Factor Receptor; Evaluation; Fiber Optics; Fluorescence; Focus Groups; Fostering; Functional disorder; Funding; Gastrointestinal tract structure; Glioma; Goals; Grant; Head and Neck Cancer; Head and neck structure; Hematologic Neoplasms; Histology; Human; Image; Image Analysis; Imaging Device; Imaging Techniques; Imaging technology; Individual; Intensity-Modulated Radiotherapy; Investigation; Ionizing radiation; Label; Laboratory Study; Lesion; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Maps; Measures; Medical; Metastatic Prostate Cancer; Metastatic to; Methodology; Methods; Michigan; Mission; Modality; Modeling; Molecular; Monitor; Motion; Mucous Membrane; Multi-Institutional Clinical Trial; Neoadjuvant Therapy; Nuclear; Oncogenic; Optics; Organ; Outcome; Patient Care; Patients; Peptides; Performance; Perfusion; Phase; Physiological; Pilot Projects; Play; Positron-Emission Tomography; Preclinical Drug Development; Premalignant; Process; Program Research Project Grants; Property; Proteins; Protocols documentation; Protons; Publications; Quality Control; Radiation; Reagent; Reporter; Research; Research Infrastructure; Research Personnel; Research Support; Resources; Risk; Schedule; Science; Scientist; Screening for cancer; Shipping; Ships; Signal Pathway; Signal Transduction; Signaling Molecule; Southwest Oncology Group; Spectrum Analysis; Staging; System; Techniques; Technology; Temperature; Therapeutic; Time; Tissues; Tracer; Training; Translating; Translational Research; Translations; Treatment Efficacy; Treatment outcome; Ultrasonography; United States National Institutes of Health; Universities; University of Michigan Comprehensive Cancer Center; Unresectable; Validation; Water; Work; anticancer research; base; bone; cancer diagnosis; cancer imaging; cancer stem cell; cancer therapy; career development; chemotherapy; clinical application; cohort; digital imaging; dosage; driving force; drug development; gemcitabine; hemodynamics; image processing; image registration; imaging Segmentation; imaging biomarker; imaging platform; imaging probe; improved; in vivo; in vivo Cellular and Molecular Imaging Centers; insight; instrument; instrumentation; irradiation; large cell Diffuse non-Hodgkin' s lymphoma; malignant breast neoplasm; meetings; member; molecular imaging; multidisciplinary; multimodality; neoplastic; new technology; non-invasive imaging; novel; oncology; oncology program; optical imaging; pre-clinical; preclinical evaluation; programs; prospective; prostate oncology; research study; response; sarcoma; screening; single photon emission computed tomography; standard of care; stem cell population; success; targeted treatment; technology development; tool; treatment response; tumor; water diffusion

The Molecular Imaging Program (MIP) consists of 19 members from 7 different departments. Since the last funding cycle the research base of the Program increased 46% from $5,740,595 total annual direct research support, of which $6,393,909 Is from the NCI. Over this last grant period, there were 188 publications of the Molecular Imaging Program, of which 28,7% were intra-programmatic and 36,7% were inter-programmatic. The program has made significant advances in developing novel technologies that facilitate diagnosis and treatment of cancer, and also has provided methodologies and reagents wherein the efficacy of various therapeutics can be monitored in real-time in pre-clinical and clinical settings. These advances include the development of novel molecular Imaging reporter molecules which have Improved our understanding of cancer etiology, biology, pathophysiology and therapy. We will continue to develop cutting edge approaches for imaging the presence of pre-malignant (dysplastic) tissue and oncogenic signaling molecules in vivo. We have developed an Integrated optical molecular Imaging strategy that uses fluorescence peptides as probes to target the presence of pre-malignant (dysplastic) tissue in vivo. The recruitment of Thomas Wang MD, PhD from Stanford University provides the MIP with new capabilities, especially the development of novel optical Imaging probes and instrumentation that can be used as a diagnostic cancer screen for early detection in variousorgans. Drs Ross, Rehemtulla and Luker will continue to develop and validate molecular imaging reporters (i.e. CXCR, c-Met and Akt), Non-invasive imaging in cells and animals will be used to evaluate these novel reporter constructs for detection of key oncogenic signaling pathways. These tools and concepts should significantly aid in our preclinical drug development process and provide insights into more efficacious combination therapy strategies for tumors. Drs Ross, Meyer and Chenevert will continue to develop novel MR-imaging based surrogates for quantification of early therapeutic efficacy in cancer patients. Recent breakthroughs in this area include the concept that analysis of changes within individual voxels (parametric response mapping, PRM) over time, provide a much more robust and predictive quantitative measure of treatment response than current approaches. Application of the PRM concept to clinical trials in brain, breast, head and neck as well as in prostate cancer metastatic to bone, have yielded results that demonstrate the early predictive power of MR-imaging especially when combined with PRM analysis.

分子成像计划(MIP)由来自7个不同部门的19名成员组成。自上一个资助周期以来，该计划的研究基础从每年5,740,595美元的直接研究资助总额增加了46%，其中6,393,909美元来自NCI。在最后一次赠款期间，分子成像计划有188份出版物，其中28.7%是计划内出版物，36.7%是项目间出版物。该计划在开发促进癌症诊断和治疗的新技术方面取得了重大进展，并提供了各种方法和试剂，其中可以在临床前和临床环境中实时监测各种疗法的疗效。这些进展包括新型分子成像报告分子的开发，这些分子提高了我们对癌症病因学、生物学、病理生理学和治疗的理解。我们将继续开发先进的方法来成像体内存在的癌前(发育不良)组织和致癌信号分子。我们已经开发了一种集成的光学分子成像策略，它使用荧光肽作为探针来定位体内存在的癌前(发育不良)组织。斯坦福大学博士Thomas Wang的招聘为MIP提供了新的能力，特别是开发了新型光学成像探针和仪器，可用作癌症诊断筛查，以便在各种器官中进行早期检测。Ross博士、Rehemtulla博士和Luker博士将继续开发和验证分子成像报告(即CXCR、c-Met和Akt)，在细胞和动物中的非侵入性成像将用于评估这些用于检测关键致癌信号通路的新型报告构建。这些工具和概念将大大有助于我们的临床前药物开发过程，并为更有效的肿瘤联合治疗策略提供见解。罗斯博士、迈耶博士和切尼韦特博士将继续开发新的基于磁共振成像的替代品，用于量化癌症患者的早期治疗效果。最近在这一领域的突破包括这样一个概念，即分析个体体素随时间的变化(参数反应映射，PRM)，提供比当前方法更稳健和更具预测性的治疗反应的定量测量。将PRM概念应用于脑、乳房、头颈部以及前列腺癌骨转移的临床试验，结果证明了磁共振成像的早期预测能力，特别是当与PRM分析相结合时。